XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows From Operating Activities:    
Net income (loss) $ (1,576,405) $ (1,762,091)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:    
Depreciation and amortization 667,298 732,702
Loss on abandonment of mineral properties 318,502 0
Amortization of debt discount 0 54,110
Accretion of asset retirement obligation 6,118 4,611
Common stock issued for services 0 136,000
Common stock payable for directors fees 89,858 96,875
Other, non cash items (661) (598)
Change in:    
Accounts receivable, net 62,399 115,451
Inventories 61,194 47,187
IVA receivable and other assets 10,119 39,501
Accounts payable (252,183) 134,237
Accrued payroll, taxes and interest (44,827) 41,325
Other accrued liabilities 70,596 47,465
Payables to related party 21,405 29,683
Net cash provided (used) by operating activities (566,587) (283,542)
Cash Flows From Investing Activities:    
Payment received on note receivable for sale of land 0 400,000
Purchase of properties, plants and equipment (220,455) (677,837)
Net cash used by investing activities (220,455) (277,837)
Cash Flows From Financing Activities:    
Change in checks issued and payable (2,879) 42,580
Net proceeds from (payment to) factor (5,032) (14,777)
Proceeds from issuance of common stock and warrants, net of issuance costs 1,813,068 431,322
Advances from related parties 0 237,400
Payments on advances from related party (64,650) (17,387)
Proceeds from note payable-SBA 443,400 0
Proceeds from notes payable to bank, net of payments (46,270) 14,311
Principal payments of long-term debt (30,876) (116,961)
Net cash provided (used) by financing activities 2,106,761 576,488
Net increase (decrease) in cash and cash equivalents 1,319,719 15,109
Cash and cash equivalents and restricted cash at beginning of period 172,767 113,897
Cash and cash equivalents and restricted cash at end of period 1,492,486 129,006
Noncash investing and financing activities:    
Common stock payable issued to directors 130,483 175,000
Payable to related party satisfied with exercise of stock purchase warrant $ 62,500 $ 0